Abstract
Abstract. Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia. It is characterized by the presence of antiphospholipid antibodies (APL) that are directed against phospholipid-binding plasma proteins, such as beta-2-glycoprotein I (b2GPI). Its main manifestations are recurrent vascular thromboses (so-called “thrombotic APS”) and pregnancy complications (“obstetric APS”). According to the current consensus criteria, a persistently positive functional lupus anticoagulant (LA) assay and/or the presence of anti-b2GPI and/or anti-cardiolipin antibodies, together with clinical symptoms, is mandatory for the diagnosis of APS. Other clinical features, such as thrombocytopenia, Coombs-positive haemolytic anaemia, heart valve disease, renal microangiopathy and neurologic disorders are also common in APL-positive patients. APS can be associated with other autoimmune disorders, such as systemic lupus erythematosus. In rare cases, catastrophic APS (CAPS) occurs, with the development of excessive thrombosis at multiple sites, usually affecting small vessels and leading to multi-organ dysfunction and organ failure. Treatment usually comprises antithrombotic therapy using antiplatelet and anticoagulant agents. However, there is no consensus concerning the intensity or duration of therapy. Despite apparently adequate anticoagulation, the risk of recurrent thrombosis remains high. For patients with CAPS, a combined therapeutic approach that includes anticoagulation, glucocorticoids, plasma exchange and/or intravenous immunoglobulin seems to be the best treatment option.
Keywords: Antiphospholipid syndrome, lupus anticoagulants, anti-cardiolipin, anti-beta-2-glycoprotein I, vascular thrombosis, pregnancy complication
Literature
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14: 71–8.
. British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome Br J Haematol. 2012;157:47–58.
The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimm Rev. 2015;14:401–14.
. Antiphospholipidsyndrom. In: Dietel, Suttorp, Zeitz. Harrisons Innere Medizin. ABW Wissenschaftsverlag 19. Auflage 2016; Berlin, Deutschland: 2623–5.
Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26:163–9.
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714–8.
, et al.; on behalf of APS Action. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review Ann Rheum Dis. 2015;74:2028–33.
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083–6.
. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011; 10:214–7.
. The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res. 2013;65:1869–73.
. Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. Autoimmun Rev. 2018;17:226–43.
, Vlachoyiannopoulos PG, El-Assaad F, Krilis SA, et al. Natural proteins involved in antiphospholipid syndrome. In: Erkan D, Lockshin (eds.) Antiphopsholipid Syndrome. Current Research Highlights and Clinical Insights.Springer 2017; Cham, Switzerland: 15–27.
. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol. 2017;178:181–95.
. Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies. Ann Med. 2014;46:693–702.
Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013). Geburtsh Frauenheilk. 2015;75:900–14.
The relevance of „non-criteria“ clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14:76–83.
. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008;22:187–94.
14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev. 2014;13:699–707.
Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J Thromb Haemost. 2018;16:529–32.
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
. Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome. Lupus. 2010;19:1071–7.
. Cutaneous manifestations of antiphospholipid syndrome: a review of the clinical features, diagnosis and management. Acta Reumatol Port. 2013;38:10–8.
. What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus. 2014;23: 1259–61.
. Revisiting Libman–Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009;36:126–30.
. What nephrologists need to know about antiphospholipid syndrome. Nephrol Dial Transplant. 2010;25:3147–54.
. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279–89.
Joint European League Against Rheumatism and European Renal AssociationEuropean Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.
. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010;40:350–9.
. Non-stroke central neurologic manifestations in antiphospholipid syndrome. Curr Rheumatol Rep. 2016;18:11.
. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015;135 Suppl 1:S56–S59.
Adrenal involvement in the antiphospholipid syndrome. Clinical and immunologic characteristics of 86 patients. Medicine. 2003;82:106–18.
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.
. Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol. 2007;34:923–6.
. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost. 2016;14:1530–48.
Update of the guidelines for lupus anticoagulant detection. Sub-committee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.
. British Committee for Standards in Haematology. British Committee for Standards in haematology. Guidelines on the investigation and management of antiphospholipid syndrome Br J Haematol. 2012;157:47–58.
. Screening for lupus anticoagulants in patients treated with vitamin K antagonists. Int J Lab Hematol. 2015;37:758–65.
. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimm Rev. 2017;16:173–8.
Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12:792–5.
. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res.2017; 153:90–4.
. Role of anti-domain 1-b2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost.2016; 14:1779–87.
Antibodies to Domain 1 (Dm1) of b2-Glycoprotein 1 (b2GP1) correctly classify patients at risk of antiphospholipid syndrome (APS). J Thromb Haemost. 2015;13:782–7.
Antibodies to Domain 4/5 (Dm4/5) of b2-Glycoprotein 1 (b2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res. 2015;136:161–3.
Anti-prothrombin (aPT) and antiphosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111:354–64.
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis. Autoimm Rev. 2014;13:595–608.
. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med. 2017;55:890–8.
. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013;52:1397–403.
Value of isolated IgA anti-b2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013;65:3186–93.
. The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. J Thromb Thrombolysis. 2016;42:552–7.
A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007;27:e309–e310.
. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993–7.
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8: 237–42.
Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology. 2015;54:2071–5.
. The global anti-phospholipid syndrome score in primary APS. Rheumatology. 2015;54:134–8.
. Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting. Lupus. 2017;26:1328–32.
. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560–7.
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus. 2011;20:206–18.
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13:281–91.
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14:192–200.
. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687–95.
Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115:2292–9.
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med. 2003;349:1133–8.
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.
Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome. Ann Hematol. 2015;94:1291–9.
. for the Subcommittees on Control of Anticoagulation and Lupus Anticoagulant/Antiphospholipid Antibodies. Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH J Thromb Haemost. 2016;14:2304–7.
. Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome. Pharmacotherapy. 2011;31:1221–31.
Parenteral Anticoagulants. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e24S–e43S.
. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005;3:2121–3.
. Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci. 2009;1173:736–45.
, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med. 2009;360:1851–61.
. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review Ann Rheum Dis. 2010;69:20–8.
. How I treat thrombotic catastrophic syndromes. Blood. 2015;126:1285–93.
. Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatol Port. 2015;40:169–75.
, et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab Autoimmun Rev. 2013;12:1085–90.
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143.
. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014: 704371.
. Antiphospholipid antibodyassociated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584–9.
. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253–7.
. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a metaanalysis of randomized controlled trials and meta-regression. Rheumatology. 2010; 49:281–8.
. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141: e691S– e736S.
. Antiphospholipid syndrome. Role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol. 2017;69: 2317–30.
Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012;119:2624–32.
. Thromboembolic disease in pregnancy and the puerperium: acute management (Green-top guideline no. 37b). Royal College of Obstetricians and Gynaecologists. 2015;1–32.
Treatment of pregnancy-associated venous thromboembolism – position paper from the Working Group in Women’s Health of the Society of Thrombosis and Haemostasis (GTH). Vasa. 2016;45:103–18.
Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19:58–64.
Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity: a European multicentre retrospective study. Thromb Haemost. 2014;112:727–35.
. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011;117:6948–51.
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev. 2015;14:498–502.
. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214:273.e1–8.
Rivaroxaban in thrombotic antiphospholipid syndrome (TRAPS) trial . https://clinicaltrials.gov/ct2/show/NCT02157272. [Accessed 04 March 2018].Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiPhospholipid Syndrome (ASTRO-APS) . https://clinicaltrials.gov/ct2/show/NCT02295475. [Accessed 4 March 2018].14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73:1176–80.
. Use of rituximab in the antiphospholipid syndrome. Curr Rheumat Rep. 2010;12:40–4.
. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthitis Rheum. 2013;65:464–71.
A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation. 2014;98: e17–e18.
Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14:459–65.
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13:2179–85.
Inhibition of the mTOR pathway in the antiphospholipid syndrome. N Eng J Med. 2014;371:303–12.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1 000 patients. Arthritis Rheum. 2002;46: 1019–27.
